Event Type
Disclosure
Mandatory
Variant
8-K
, “ Entry into a Material Definitive Agreement – Indemnification Agreement ,” “ - BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan ” a
of this Current Report is incorporated herein by reference. 12 Effective immediately following the Merger Effective Time, Eli Wallace, Neil Kumar, Frank McCormi
. Unregistered Sale of Equity Securities PubCo issued certain securities described in the Introductory Note under Section 4(a)(2) of the Securities Act, in tran
. Material Modification to Rights of Security Holders In connection with the consummation of the Business Combination, Helix migrated and domesticated as a Dela
. Change in Registrant’s Certifying Accountant (a) Dismissal of independent registered public accounting firm. On August 11, 2025, PubCo Board dismissed WithumS
. Changes in Control of Registrant Reference is made to the disclosure in the Proxy Statement/Prospectus in the section titled “ Proposal No. 1: The Business Co
. Amendments to Articles of Incorporation or By-laws; Change in Fiscal Year. At the EGM, Helix shareholders considered and approved Proposal No. 2: The Domestic
, including Exhibit 99.4. Item 8.01 Other Information By operation of Rule 12g-3(a) under the Exchange Act, PubCo is the successor issuer to Helix and has succe
, in accordance with Rule 12g-3(a) under the Exchange Act, PubCo is the successor issuer to Helix and has succeeded to the attributes of Helix as the registrant
. Financial Statements and Exhibits (a) Financial statements of businesses acquired. The financial statements of BBOT as of and for the years ended December 31,